0001562180-24-005854.txt : 20240726 0001562180-24-005854.hdr.sgml : 20240726 20240726164757 ACCESSION NUMBER: 0001562180-24-005854 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240726 FILED AS OF DATE: 20240726 DATE AS OF CHANGE: 20240726 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lurker Nancy CENTRAL INDEX KEY: 0001450485 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 241147707 MAIL ADDRESS: STREET 1: PDI, INC. STREET 2: 1 ROUTE 17 SOUTH CITY: SADDLE RIVER STATE: NJ ZIP: 07458 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2024-07-26 false 0001314102 EyePoint Pharmaceuticals, Inc. EYPT 0001450485 Lurker Nancy C/O EYEPOINT PHARMACEUTICALS, INC. 480 PLEASANT STREET WATERTOWN MA 02472 true false false false false Stock Option (Right to Buy) 12.90 2024-07-26 4 G false 1558.00 0.00 D 2030-02-28 Common Stock 1558.00 0.00 D Stock Option (Right to Buy) 12.90 2024-07-26 4 G false 1558.00 0.00 A 2030-02-28 Common Stock 1558.00 74800.00 I By Family Trust Stock Option (Right to Buy) 13.13 2024-07-26 4 G false 26713.00 0.00 D 2031-02-09 Common Stock 26713.00 31165.00 D Stock Option (Right to Buy) 13.13 2024-07-26 4 G false 26713.00 0.00 A 2031-02-09 Common Stock 26713.00 182535.00 I By Family Trust Stock Option (Right to Buy) 10.13 2024-07-26 4 G false 30000.00 0.00 D 2032-02-09 Common Stock 30000.00 95000.00 D Stock Option (Right to Buy) 10.13 2024-07-26 4 G false 30000.00 0.00 A 2032-02-09 Common Stock 30000.00 145000.00 I By Family Trust Stock Option (Right to Buy) 3.26 2024-07-26 4 G false 56350.00 0.00 D 2033-01-05 Common Stock 56350.00 281750.00 D Stock Option (Right to Buy) 3.26 2024-07-26 4 G false 56350.00 0.00 A 2033-01-05 Common Stock 56350.00 169050.00 I By Family Trust Stock Option (Right to Buy) 9.11 2024-07-26 4 G false 16666.00 0.00 D 2033-07-10 Common Stock 16666.00 50000.00 D Stock Option (Right to Buy) 9.11 2024-07-26 4 G false 16666.00 0.00 A 2033-07-10 Common Stock 16666.00 16666.00 I By Family Trust On July 26, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025. The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026. The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until January 6, 2027. The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until July 10, 2027. /s/ Ron Honig, Attorney-in-Fact 2024-07-26